Andy Lane, PhD
Andy Lane is the commercial director at The Native Antigen Company. Andy studied pathobiology at the University of Reading and completed a PhD in antibody immunotherapy at the University of Southampton. He then joined the NHS and led a monoclonal antibody research group working in leukemia and lymphoma diagnostics. Andy subsequently joined a major monoclonal antibody supplier to lead their new product development. More recently, he was executive director at bioconjugation specialists Innova Biosciences before joining The Native Antigen Company in 2016.
Articles by Andy Lane, PhD
|3 min read
Preparing for Disease Y: A Better Serological Toolbox
Why a broader range of general-purpose reagents are needed for the next pandemic
|3 min read
Fine-Tuned Diagnostics Needed to Assess COVID-19 Vaccine-Induced Responses
Assessment of vaccine-induced immune responses in clinical trials will require highly specific diagnostic assays to ensure safety
|3 min read
Better Access to Reagents Is Needed for Neglected Tropical Disease Research
Lack of critical reagents is an overlooked barrier to NTD product developmentPage 1 of 1
